Development and introduction of a pediatric liquid formulation of 6-mercaptopurine for treatment of leukemia.

Trial Profile

Development and introduction of a pediatric liquid formulation of 6-mercaptopurine for treatment of leukemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 May 2014

At a glance

  • Drugs Mercaptopurine (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms 6MP formulation
  • Most Recent Events

    • 07 May 2014 Primary endpoint 'Patient-assessment-of-acceptability' has been met.
    • 07 May 2014 Primary endpoint 'Drug-bioavailability' has been met.
    • 07 May 2014 Results published in the International Journal of Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top